Summit Securities Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-150
Closed -$1.28M – 340
2019
Q2
$1.28M Buy
+150
New +$12.8K 0.15% 110

Other funds holding BMRN

Summit Securities Group's BMRN Position: Q3 2026 in Review

Summit Securities Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 999 shares worth $59.9K. The stake represents 0.01% of the portfolio and ranks #535 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in BMRN as recently as Q2 2019.

Summit Securities Group first reported a position in BMRN in Q2 2019 and has held it in 2 quarters since. The position peaked at $514K in Q2 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Summit Securities Group held 999 shares of BioMarin Pharmaceuticals worth $59.9K as of Q3 2026.
  • BioMarin Pharmaceuticals was a new Summit Securities Group position in Q3 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Summit Securities Group's portfolio in Q3 2026, its #535 holding.
  • Summit Securities Group first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 2 quarters since.
  • Summit Securities Group's BioMarin Pharmaceuticals position peaked at $514K in Q2 2019.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.